Macrogenics Inc
MGNX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001125345
In the last 90 days, Macrogenics Inc insiders filed 0 open-market purchases and 1 sale; 122 institutions reported holding it in 13F filings for Q2 2026, worth $224.9M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $140.6M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $129.1K in total
- 1
- 13F holdersQ2 2026, +13 vs. previous quarter
- 122
- 13F valueReported value at the end of Q2 2026
- $224.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $149.5M
- −0.3% year over year
- Net income, FY2025
- -$74.6M
- No comparable prior period
- Free cash flow, FY2025
- -$83.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $18.7M
- −74.4% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $74.6M (49.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 4.95M
- Shares sold short
- Change
- −110.7K
- −2.2% vs. previous
- Days to cover
- 3.86
- At average daily volume
Superinvestors holding MGNX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding MGNX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Macrogenics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 (view filing)6:19 PM ET | Aug 19 | 1 day | Peters Jeffrey StuartSenior VP, GC, and Secretary | SSale | −31.1K | $4.15 | −$129.1K | −100.0%0 after | 10b5-1 |
| Aug 21, 2025 (view filing) | Aug 19-20 | 2 days | Heiden William KDirector | PPurchase | +100.0K | $1.51 | +$150.5K | +909.1%111.0K after | 2 lots |
| Feb 19, 2025 (view filing) | Feb 15 | 4 days | Smith Beth AnnVP, Controller & Treasurer | SSale | −423 | $2.56 | −$1.08K | −4.2%9.53K after | |
| Apr 8, 2024 (view filing) | Apr 4 | 4 days | Peters Jeffrey StuartSenior VP and General Counsel | SSale | −51.4K | $15.55 | −$799.1K | −100.0%0 after | 5 lots10b5-1 |
| Mar 8, 2024 (view filing) | Mar 6 | 2 days | Peters Jeffrey StuartSenior VP and General Counsel | SSale | −19.6K | $21.50 | −$421.9K | −68.8%8.89K after | 10b5-1 |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Risser Eric BlasiusChief Operating Officer | SSale | −41.2K | $19.76 | −$813.5K | −51.4%38.9K after | 2 lots10b5-1 |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Spitznagel ThomasSr VP, Technical Ops | SSale | −10.0K | $20.00 | −$200.0K | −54.6%8.32K after | 10b5-1 |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Karrels JamesSVP, CFO and Secretary | SSale | −30.0K | $20.50 | −$615.0K | −14.9%171.5K after | 10b5-1 |
| Feb 28, 2024 (view filing) | Feb 26 | 2 days | Peters Jeffrey StuartSenior VP and General Counsel | SSale | −16.1K | $17.22 | −$277.7K | −64.4%8.89K after | 10b5-1 |
| Feb 7, 2024 (view filing) | Feb 7 | Same day | Bonvini EzioSr VP, Research & CSO | SSale | −3.33K | $18.00 | −$60.0K | −4.5%71.3K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 122 holdersThe largest institutional positions in Macrogenics Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 5,006,752 | $23.1M | 0.64% | −1,005,248−16.7% | Reduced |
| BlackRock, Inc. | 4,679,229 | $21.6M | 0.00% | +3,516,083+302.3% | Added |
| Vanguard Capital Management LLC | 2,656,010 | $12.3M | 0.00% | +2,157+0.1% | Added |
| Renaissance Technologies LLC | 2,632,750 | $12.2M | 0.02% | −330,809−11.2% | Reduced |
| Acadian Asset Management LLC | 2,542,643 | $11.7M | 0.01% | −1,357−0.1% | Reduced |
| Bank of America Corp | 2,488,252 | $11.5M | 0.00% | +86,438+3.6% | Added |
| Two Sigma Investments, LP | 2,465,699 | $11.4M | 0.01% | −62,130−2.5% | Reduced |
| Millennium Management LLC | 2,374,296 | $11.0M | 0.01% | −420,061−15.0% | Reduced |
| Wasatch Advisors Inc | 2,018,881 | $9.33M | 0.06% | +459,180+29.4% | Added |
| Ra Capital Management, L.P. | 1,864,176 | $8.61M | 0.07% | 00.0% | Unchanged |
Holders of 5% or more of MGNX
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Macrogenics Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 13G/A | 9.45%5.96M shares | – | Aug 14, 20251 filing | Aug 14, 2025 | SEC |
| Armistice Capital, LLC | 13G/A | 7.88%5.01M shares | −1.58 ppfrom 9.46% | Feb 14, 20238 filings | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G | 7.10%4.50M shares | +4.20 ppfrom 2.90% | Oct 22, 20244 filings | Jul 29, 2026 | SEC |